{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 95 of 129', 'Primary analyses for the secondary estimand (continuous secondary endpoints)', 'Data retrieved at Week 16 for subjects who have permanently discontinued IMP prior to', 'Week 16 will be included in the analysis. Missing Week 16 data will be imputed using', 'multiple imputations assuming that data is missing at random within the groups used for', 'imputation.', 'Imputation of missing data at Week 16 will be done using multiple imputations within', '4 groups defined according to randomised treatment arm and whether or not subjects have', 'discontinued treatment prior to Week 16. Within a given treatment arm, retrieved data from', 'discontinued subjects will be used to impute missing data for other discontinued subjects.', 'Similarly, the available data from not discontinued subjects will be used to impute data for', 'such subjects where the Week 16 value is missing.', 'For not discontinued subjects, the stepwise multiple imputations procedure will be conducted', 'in the same way as specified for the imputation of the underlying EASI values in the primary', 'analysis of the secondary estimand for the binary endpoints.', 'For discontinued subjects, it is expected that the number of subjects with retrieved data at', 'Week 16 will be too small to facilitate the same imputation model as mentioned just above.', 'Consequently, an imputation model with only region and baseline effects (IGA as a factor and', 'baseline SCORAD / DLQI as a covariate) will be applied for discontinued subjects. Some', 'factors may have to be omitted, depending on the observed data, e.g. if retrieved subjects only', 'come from one region or if they all have the same baseline severity.', 'Each of the 100 imputed datasets will be analysed as described in the sensitivity analyses for', 'the primary estimand for the continuous secondary endpoints.', 'Sensitivity analyses for the secondary estimand (continuous secondary endpoints)', 'Rather than assuming that observations are missing at random, it is assumed that missing data', 'from subjects in the tralokinumab+TCS arm who have/have not discontinued treatment prior', 'to Week 16 will resemble data from subjects from the placebo+TC arm who have/have not', 'discontinued treatment prior to Week 16.', 'Imputation of missing data at Week 16 will be done using a pattern mixture model where', 'missing data in the tralokinumab+TCS arm as well as the placebo+TCS arm will be imputed', 'from the placebo+TCS arm (copy-reference approach). With this exemption, the multiple', 'imputation procedure and analysis will be conducted in the same way as described for the', 'primary analysis of the secondary estimand for the continuous secondary endpoints.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 96 of 129', '12.3.7 Analysis of additional secondary endpoints', 'Initial treatment period', 'The analysis of the below additional secondary endpoints will be based on the primary', 'analyses of the primary estimand as specified above for the relevant primary dichotomous', 'endpoints and continuous secondary endpoints, respectively.', 'The following dichotomous additional secondary endpoints will be analysed according to the', 'primary analysis of the primary estimand for the primary endpoints:', 'EASI50 at Week 16.', 'EASI90 at Week 16.', 'SCORAD50 at Week 16.', 'SCORAD75 at Week 16.', 'Reduction from baseline (Y/N) of DLQI of >4 points (in subjects with baseline', 'DLQI>4) at Week 16.', 'The change from baseline to Week 16 in EASI score and the change from baseline to Week 16', 'in Worst Daily Pruritus NRS weekly average will be analysed according to the primary', 'analysis of the primary estimand for the continuous secondary endpoints.', 'To evaluate the efficacy related to health care resource utilisation, the amount of TCS used', '(assessed as the amount of TCS used between visits), and the number of days without topical', 'treatment use (collected as Patient Days of Topical Treatment Use in the eDiary) will be', 'determined by 2-week periods. The amount of TCS used and the number of days without', 'topical treatment use will each be analysed by a repeated measurements model with an', 'unstructured covariance matrix and the mean modelled as follows:', 'Y = treatment X visit + region + baseline IGA', 'Results obtained after initiation of rescue treatment will be excluded from the analyses.', 'AD flares will be summarised descriptively as the proportion of subjects having had AD flares', 'at Week 16, the number of AD flares from baseline to Week 16, and the rate of AD flares from', 'baseline to Week 16. The rate of AD flares will be defined as the number of AD flares divided', 'by time at risk, where the time at risk for each subject is the time from treatment start to last', 'visit attended up to Week 16.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}